Title: 2022 Sinemet (Parkinson’s Disease) Forecast and Market Analysis
1Sinemet (Parkinsons Disease) Forecast and
Market Analysis to 2022
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_marketoptimizer.org with
your contact details and questions if any.
- Published Mar 2014
- Single User PDF US 3495
- Corporate User PDF US 10485
2Sinemet (Parkinsons Disease) Forecast and
Market Analysis to 2022
- Parkinsons disease is a progressive condition
that is characterized by bradykinesia, muscular
rigidity, tremor, and postural instability. As
the second most common neurodegenerative
disorder, Parkinsons disease may affect
individuals of any age but prevalence is
increased with age and it is most common in the
elderly. Dopaminergic therapies have been fairly
effective in treating bradykinesia, but several
unmet needs remain. Some needs will be met during
the forecast period from 2012-2022, while others,
such as the need for disease-modifying drugs,
will remain. - Researcher expects that advancements will be made
in levodopa administration and that four new
molecular entities will be introduced to the
market by 2022, these factors along with
increased patient numbers from an aging
population will drive the market during the
forecast period.
Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
3Sinemet (Parkinsons Disease) Forecast and
Market Analysis to 2022
- Sinemet (carbidopa and levodopa), developed by
Merck Co., is considered one of the gold
standards for treatment in Parkinsons disease. - It is used for the control of motor symptoms in
Parkinsons disease and other Parkinsonian
syndromes. - Sinemet does not slow the neurodegenerative
process in Parkinsons disease, and over time
patients responsiveness to therapy may change as
they enter more advanced stages of the disease. - Inquire about this report at http//www.marketopti
mizer.org/contacts/purchase?rname7284
Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
4Sinemet (Parkinsons Disease) Forecast and
Market Analysis to 2022
- Scope
- Overview of Parkinsons disease, including
epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an
overview on the competitive landscape. - Detailed information on Sinemet including product
description, safety and efficacy profiles as well
as a SWOT analysis. - Sales forecast for Sinemet for the top eight
countries from 2012 to 2022. - Sales information covered for the US, France,
Germany, Italy, Spain, the UK, Japan and Brazil.
Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
5Sinemet (Parkinsons Disease) Forecast and
Market Analysis to 2022
- Reasons to buy
- Understand and capitalize by identifying products
that are most likely to ensure a robust return - Stay ahead of the competition by understanding
the changing competitive landscape for
Parkinsons disease - Effectively plan your MA and partnership
strategies by identifying drugs with the most
promising sales potential - Make more informed business decisions from
insightful and in-depth analysis of Sinemet
performance - Obtain sales forecast for Sinemet from 2012-2022
in the top eight countries (the US, France,
Germany, Italy, Spain, the UK, Japan and Brazil). - Get a detailed report at http//www.marketoptimiz
er.org/sinemet-parkinsons-disease-forecast-and-mar
ket-analysis-to-2022.html .
Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
6Sinemet (Parkinsons Disease) Forecast and
Market Analysis to 2022
- About Us
- marketoptimizer.org is an online market research
reports library of 250,000 in-depth studies of
over 5000 micro markets. Our database includes
reports by leading publishers from across the
globe. We provide 24/7 online and offline support
service to our customers. marketoptimizer.org
also offers company data, country profiles,
trends, information and analysis on the sector of
your interest. - Visit Us _at_
- http//www.marketoptimizer.org
- Follow Us
Call Now 1 888 391 5441 Email sales _at_
sales_at_marketoptimizer.org